title: Cutaneous vascular function during acute hyperglycemia in healthy young adults.
abstract: Although it is well established that severe chronic hyperglycemia is associated with microvascular disease, it is not known whether transient hyperglycemia similar to that observed with impaired glucose tolerance or early Type 2 diabetes contributes to this pathology by altering microvascular function. To test the hypothesis that acute hyperglycemia decreases microvascular vasodilator responsiveness in human skin, we measured the cutaneous vasodilator response to local warming. This response can be divided into two phases, an initial peak that relies predominantly on local sensory nerves and a second slower phase that is largely dependent on endothelial nitric oxide. We reasoned that a change in one or both phases would indicate a change in the corresponding mechanism(s) with hyperglycemia. Twenty-eight healthy volunteers (14 women, 14 men) were randomly divided into three groups, corresponding to 6 h of euglycemia (n = 8), 6 h when glucose was clamped at approximately 7 mmol/l (n = 10), or 6 h when glucose was varied to mimic a postprandial pattern (i.e., peak glucose approximately 11.1 mmol/l) commonly observed in individuals with impaired glucose tolerance (n = 10). Insulin concentrations in all instances were maintained at approximately 65 pmol/l by means of continuous infusions of somatostatin and insulin. Glucagon and growth hormone were also continuously infused to maintain their basal concentrations. Despite substantial differences in both the level and pattern of glucose concentrations, neither maximum cutaneous vasodilation nor the pattern of the vasodilator response to local warming differed over the 6 h of study. We conclude that acute hyperglycemia similar to levels commonly observed in people with either early Type 2 diabetes or impaired glucose tolerance does not alter the vasodilator response to local warming of the skin in humans.
authors.affiliation: Department of Anesthesiology, General Clinical Research Center, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: N
authors.initials: N
authors.lastname: Charkoudian
authors.forename: A
authors.initials: A
authors.lastname: Vella
authors.forename: A S
authors.initials: AS
authors.lastname: Reed
authors.forename: C T
authors.initials: CT
authors.lastname: Minson
authors.forename: P
authors.initials: P
authors.lastname: Shah
authors.forename: R A
authors.initials: RA
authors.lastname: Rizza
authors.forename: M J
authors.initials: MJ
authors.lastname: Joyner
mesh_terms: D000208:Acute Disease; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D001808:Blood Vessels / Q000503:physiopathology; D002096:C-Peptide / Q000097:blood; D005260:Female; D018149:Glucose Intolerance / Q000503:physiopathology; D006439:Hemodynamics; D006358:Hot Temperature; D006801:Humans; D006943:Hyperglycemia / Q000503:physiopathology*; D007328:Insulin / Q000097:blood; D008297:Male; D009994:Osmolar Concentration; D012016:Reference Values; D012039:Regional Blood Flow; D012867:Skin / Q000098:blood supply*; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin